Nanomedicine Faces Barriers
AbstractTargeted nanoparticles have the potential to improve drug delivery efficiencies by more than two orders of magnitude, from the ~ 0.1% which is common today. Most pharmacologically agents on the market today are small drug molecules, which diffuse across the body’s blood-tissue barriers and distribute not only into the lesion, but into almost all organs. Drug actions in the non-lesion organs are an inescapable part of the drug delivery principle, causing “side-effects” which limit the maximally tolerable doses and result in inadequate therapy of many lesions. Nanoparticles only cross barriers by design, so side-effects are not built into their mode of operation. Delivery rates of almost 90% have been reported. This review examines the significance of these statements and checks how far they need qualification. What type of targeting is required? Is a single targeting sufficient? What new types of clinical challenge, such as immunogenicity, might attend the use of targeted nanoparticles?
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Debbage, P.; Thurner, G.C. Nanomedicine Faces Barriers. Pharmaceuticals 2010, 3, 3371-3416.
Debbage P, Thurner GC. Nanomedicine Faces Barriers. Pharmaceuticals. 2010; 3(11):3371-3416.Chicago/Turabian Style
Debbage, Paul; Thurner, Gudrun C. 2010. "Nanomedicine Faces Barriers." Pharmaceuticals 3, no. 11: 3371-3416.